Patient-Centered Care for the Older Adult With Hematologic Malignancy

NCT02359838 | Completed Results DMC

• 1 other identifier: 14-515
• Study Type: interventional
• Target: 160
• Locations: 1 country
• Sites: 1

Brief Summary

This research study is evaluating if co-management by a geriatrician embedded in the oncology clinic can improve outcomes for frail older adults with blood cancers. A rigorous pre-entry frailty assessment by a trained research assistant will be followed by randomization to geriatrician co-management versus usual care for patients found to be frail or pre-frail.

Conditions

Hematologic Malignancy

Keywords

Hematologic Malignancy; Geriatric Assessment; Geriatric Oncology; Frailty

Outcome Measures

Primary Outcomes (1)

• Overall Survival

  Overall Survival at one year

  One year

Study Arms (2)

Usual Care

OTHER

Frail/pre-frail hematologic oncology patients receive usual care

Other: Baseline Geriatric Screening/Assessment

Geriatrician Co-Management

ACTIVE COMPARATOR

Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician

Other: Baseline Geriatric Screening/Assessment; Other: Geriatrician Co-Management

Interventions

Baseline Geriatric Screening/Assessment OTHER

All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.

Geriatrician Co-Management; Usual Care

Geriatrician Co-Management OTHER

A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.

Geriatrician Co-Management

Eligibility Criteria

• Age: 75 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• All patients aged 75 and older who present for an initial consultation at the Dana-Farber/Brigham and Women's Cancer Center for hematologic malignancy (transplantation consultation excluded).
• Assessed to be pre-frail or frail on formal baseline geriatric assessment.

You may not qualify if:

• Not willing to participate

Sponsors & Collaborators

• Dana-Farber Cancer Institute: lead

Study Sites (1)

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States

Location

Related Links

• Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies

MeSH Terms

Conditions

Hematologic Neoplasms; Frailty

Interventions

Restraint, Physical

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Behavior Control; Therapeutics; Immobilization; Investigative Techniques

Results Point of Contact

• Title: Gregory A. Abel
• Organization: Dana-Farber Cancer Institute

gregory_abel@dfci.harvard.edu

617-632-2304

Study Officials

• Gregory A. Abel, MD, MPH

  Dana Faber Cancer Institute

  PRINCIPAL INVESTIGATOR

• Jane A Driver, MD, MPH

  Brigham and Women's Hospital

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: February 2, 2015
• First Posted: February 10, 2015
• Study Start: February 1, 2015
• Primary Completion: May 1, 2018
• Study Completion: May 1, 2020
• Last Updated: July 19, 2022
• Results First Posted: July 19, 2022

Record last verified: 2022-03

Locations

US (1)